LATEST PUBLICATIONSConventional and Neo-Antigenic Peptides Presented by β Cells Are Targeted by Circulating Naïve CD8+ T Cells in Type 1 Diabetic and Healthy Donors Gonzales-Duque S, Azoury ME, Colli ML, Afonso G, Turatsinze JV, Nigi L, Lalane AI, Sebastiani G, Carré A, Pinto S, Culina S, Crocos N, Bugliani M, Marchetti P, Armanet M, Diedisheim M, Kyewski B, Steinmetz LM, Buus S, You S, Dubois-Laforgue D, Larger E, Beressi JP, Bruno G, Dotta F, Scharfmann R, Eizirik DL, Verdier Y, Vinh J, Mallone R Cell Metab 2018 
Islet-reactive CD8+ T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors Culina S, Lalanne AI, Afonso G, Cerosaletti K, Pinto S, Sebastiani G, Kuranda K, Nigi L, Eugster A, Osterbye T, Maugein A, McLaren JE, Ladell K, Larger E, Beressi JP, Lisina A, Appay V, Davidson HW, Buus S, Price DA, Kuhn M, Bonifacio E, Battaglia M, Caillat-Zucman S, Dotta F, Scharfmann R, Kyewski B, Mallone R, ImMaDiab Study Group Sci Immunol 2018 Maternal-fetal transfer of preproinsulin through the neonatal Fc receptor prevents autoimmune diabetes
Slobodan C, Gupta N, Boisgard R, Afonso G, Gagnerault MC, Dimitrov J, Osterbye T, Justesen S, Luce S, Attias M, Kyewski B, Buus S, Wong FS, Lacroix-Desmazes S, Mallone R Diabetes 2015 Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance
Gupta N, Culina S, Meslier Y, Dimitrov J, Arnoult C, Delignat S, Gangadharan B, Lecerf M, Justesen S, Gouilleux-Gruart V, Salomon BL, Scott DW, Kaveri SV, Mallone R, Lacoirx-Desmazes S Sci Transl Med 2015 Of Bugs and Men: Antigen-Fortified Lactococcus lactis for Type 1 Diabetes Immunotherapy
Mallone R, Culina S Diabetes 2014 HLA-B7-restricted islet epitopes are differentially recognized in type 1 diabetic children and adults and form weak peptide-HLA complexes.
Scotto M, Afonso G, Østerbye T, Larger E, Luce S, Raverdy C, Novelli G, Bruno G, Gonfroy-Leymarie C, Launay O, Lemonnier FA, Buus S, Carel JC, Boitard C, Mallone R. Diabetes. 2012 Zinc transporter (ZnT)8(186-194) is an immunodominant CD8+ T cell epitope in HLA-A2+ type 1 diabetic patients.
Scotto M, Afonso G, Larger E, Raverdy C, Lemonnier FA, Carel JC, Dubois-Laforgue D, Baz B, Levy D, Gautier JF, Launay O, Bruno G, Boitard C, Sechi LA,Hutton JC, Davidson HW, Mallone R. Diabetologia.2012 acDCs enhance human antigen-specific T-cell responses.
Martinuzzi E, Afonso G, Gagnerault MC, Naselli G, Mittag D, Combadière B, Boitard C, Chaput N, Zitvogel L, Harrison LC, Mallone R. Blood. 2011 Beyond the hormone: insulin as an autoimmune target in type 1 diabetes.
Brezar V, Carel JC, Boitard C, Mallone R. Endocr Rev. 2011 |
Bienvenus sur le site du Laboratoire DeARLab
Le Laboratoire de Recherche sur le Diabète et l’Auto-immunité (DeARLab) a été établi en 2007à l'Institut Cochin. Il est affilié à l’Inserm (Institut National de la Santé et de la Recherche Médicale) , à l’Université Paris Descartes et à l’Assistance Publique/Hôpitaux de Paris. En 2008, il est devenu équipe "Avenir", un label d’excellence attribué par l’Inserm à des jeunes équipes qui lancent une thématique de recherche nouvelle et prometteuse. Notre objectif est de comprendre la pathogenèse immunitaire du diabète de type 1 et d’autres maladies auto-immunes. Grâce à des technologies innovantes, nous visons à développer des protocoles de suivi et intervention immunologique pour la classification diagnostique, le traitement et la prévention des maladies auto-immunes. Bonne visite ! Roberto Mallone, MD PhD Sylvaine You, PhD 
Welcome to the DeARLab Website The Diabetes & Autoimmunity Research Laboratory was established in 2007 at the Cochin Institut. It is affiliated with Inserm (Institut National de la Santé et de la Recherche Médicale), the University Paris Descartes and the Assistance Publique/Hôpitaux de Paris. In 2008, it received the "Avenir" label, a prestigious honor assigned by Inserm to young research groups starting a novel high-impact line of research. Our focus is the understanding of the immune pathogenesis of type 1 diabetes and other autoimmune disorders. Through development of innovative technologies, we aim at obtaining "immune staging" protocols for diagnostic classification, treatment and therapeutic prevention of autoimmune diseases. Hope you will enjoy your visit! Roberto Mallone, MD PhD Sylvaine You, PhD |
aa
OUR PARTNERS
|
